Sponsor:
University of Erlangen-Nürnberg Medical School
Collaborator:
-
Studienleiter
Oliver Ott, MD Principal Investigator Dept. of Radiation Therapy, University Hospital Erlangen
Kontakt
Oliver Ott, MD Kontakt: Phone: ++49(0)913185 Phone (ext.): 33968 E-Mail: oliver.ott@uk-erlangen.de» Kontaktdaten anzeigen
Studienlocations (1 von 1)
Dept. of Radiation Therapy, University Hospital Erlangen 91054 Erlangen (Bayern) GermanyRekrutierend» Google-Maps Ansprechpartner: Oliver Ott, MD» Ansprechpartner anzeigen
1. Overall survival (Time Frame - Participants will be followed for up to 5 years after the end of therapy): Overall survival
Secondary outcome:
1. Bladder preservation rate (Time Frame - Participants will be followed for up to 5 years after the end of therapy): Rate of patients where bladder can be preserved
2. Disease free survival (Time Frame - Participants will be followed for up to 5 years after the end of therapy): Length of survival without disease recurrence
Hyperthermia (Thermal therapy or thermotherapy): Deep Regional Hyperthermia (RHT) 1-2/week up to 10 sessions a type of cancer treatment in which body tissue is exposed to high temperatures (up to 113°F).
Radiotherapy: 50,4 Gy (28 x 1,8 Gy) plus Boost: If R0: 5,4 Gy; If R1/2: 9 Gy
Chemotherapy 5-Fluorouracil: 600 mg/m^2 civ 120h; d 1-5, 29-33
Chemotherapy Cisplatin: 20 mg/m^2; d1-5, 29-33
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!